February 25, 2021
UC San Diego was awarded five COVID-19 Rapid Acceleration of Diagnostics (RADx) projects by the National Institutes of Health totaling nearly $33 million, which will fund efforts that range from managing a large data center to expanding testing in disadvantaged communities.
August 5, 2021
UC San Diego researchers report that solid organ transplant recipients who were vaccinated experienced an almost 80 percent reduction in the incidence of symptomatic COVID-19 compared to unvaccinated counterparts during the same time.
May 12, 2021
Researchers at UC San Diego School of Medicine have begun a pilot clinical trial to test the efficacy of using ultrasound to stimulate the spleen and reduce COVID-19-related inflammation, decreasing the length of hospital stays.
May 29, 2020
A $1 million gift from the John and Mary Tu Foundation is helping to increase the number of people tested for COVID-19, as well as develop new ways to track and treat the virus.
August 5, 2020
The National Institutes of Health will soon launch a Phase II clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including the use of investigational synthetic monoclonal antibodies. Davey Smith of UC San Diego is the protocol chair and answers questions.
April 7, 2020
With support from Amazon Web Services, UC San Diego Health physicians are using AI in a clinical research study aimed at speeding the detection of pneumonia, a condition associated with severe COVID-19.
March 26, 2020
Researchers at University of California San Diego School of Medicine are launching a pair of studies to answer critical questions regarding the roles COVID-19 may play in breast milk and pregnancy.
April 30, 2020
UC San Diego scientists have launched a clinical trial to investigate whether a drug approved for treating high blood pressure might also reduce the severity of COVID-19 infections, lowering rates for intensive care unit admissions, the use of mechanical ventilators and all-cause mortality.
April 27, 2020
Researchers at UC San Diego Health report in newly published findings that olfactory impairment suggests the resulting COVID-19 disease is more likely to be mild to moderate, a potential early indicator that could help health care providers determine which patients may require hospitalization.
December 1, 2020
A team of SDSC researchers recently created a pharmacophore model and conducted data mining of the database of drugs approved by the U.S. Federal Drug Administration (FDA) to find potential inhibitors of papain-like protease of SARS-CoV2, one of the main viral proteins responsible for COVID-19
